VBIV News and Press, VBI Vaccines Inc. From 11/11/22

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that its abstract highlighting data from the ongoing Phase 2a study of VBI-1901, the Company’s cancer vaccine i...

VBI Vaccines press release ( NASDAQ: VBIV ): Q3 GAAP EPS of -$0.10 misses by $0.02 . Revenue of $0.32M (+190.9% Y/Y) misses by $0.97M . VBI ended the third quarter of 2022 with $83.6 million in cash compared with $121.7 million in cash as of December 31, 2021. ...

Q3 marked a meaningful quarter for partnerships with a recently announced prophylactic hepatitis B commercialization collaboration in certain European countries with Valneva , and a clinical collaboration in glioblastoma with Agenus PreHevbrio™ [Hepatitis B Vaccine ...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, and David E. Anderson, Ph.D., VBI’s Chief Scientific Offi...

- Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022 - Study expected to assess VBI-1901 with concurrent balstilimab (anti-PD-1) administration in frontline Glioblastoma (GBM) patients following primary tumor ...

Initiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses Preclinical data support broadly reactive immunity of VBI-2901 against a panel of coronavirus variants in mice, which now also includes...

Summary VBI Vaccines has not been immune to sell-off with their share price shrinking by roughly 75% over the past year despite the company making significant headway both clinically and commercially. VBIV is still in my Compounding Healthcare "Bio Boom" speculative portfolio. The...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the physician-initiated compassionate use of VBI’s 3-antigen hepatitis B vaccine in four adu...

VBI Vaccines ( NASDAQ: VBIV ) said it signed an agreement for a refinanced and upsized debt facility of up to $100M with its existing lender K2 HealthVentures. Under the agreement, $50M is immediately available upon closing, consisting of $30M to refinance an outstandi...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVe...